Thiogenesis Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Thiogenesis Therapeutics.
Thiogenesis Therapeutics Overview
About Thiogenesis Therapeutics
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company’s compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Founded
2018
HQ
Employees
N/A
Website
Financials (FY)
EV
$21M
Valuation Multiples
Start free trial
Thiogenesis Therapeutics Financials
Thiogenesis Therapeutics reported last fiscal year revenue of - and negative EBITDA of ($5M).
In the same fiscal year, Thiogenesis Therapeutics generated ($5M) in EBITDA losses and had net loss of ($5M).
Thiogenesis Therapeutics P&L
In the most recent fiscal year, Thiogenesis Therapeutics reported revenue of - and EBITDA of ($5M).
Thiogenesis Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Thiogenesis Therapeutics Stock Performance
Thiogenesis Therapeutics has current market cap of $21M, and enterprise value of $21M.
Thiogenesis Therapeutics' stock price is $0.41.
Thiogenesis Therapeutics has an EPS (earnings per share) of $-0.10.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21M | $21M | 3.5% | - | - | - | $-0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialThiogenesis Therapeutics Valuation Multiples
Thiogenesis Therapeutics trades at (3.9x) EV/EBITDA.
Thiogenesis Therapeutics Financial Valuation Multiples
As of August 14, 2026, Thiogenesis Therapeutics has market cap of $21M and EV of $21M.
Thiogenesis Therapeutics has a P/E ratio of (3.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Thiogenesis Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Thiogenesis Therapeutics Margins & Growth Rates
Thiogenesis Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Thiogenesis Therapeutics Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Thiogenesis Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Thiogenesis Therapeutics
| When was Thiogenesis Therapeutics founded? | Thiogenesis Therapeutics was founded in 2018. |
| Where is Thiogenesis Therapeutics headquartered? | Thiogenesis Therapeutics is headquartered in Canada. |
| Is Thiogenesis Therapeutics publicly listed? | Yes, Thiogenesis Therapeutics is a public company listed on Toronto Stock Exchange. |
| What is the stock symbol of Thiogenesis Therapeutics? | Thiogenesis Therapeutics trades under TTI ticker. |
| When did Thiogenesis Therapeutics go public? | Thiogenesis Therapeutics went public in 2022. |
| Who are competitors of Thiogenesis Therapeutics? | Thiogenesis Therapeutics main competitors include |
| What is the current market cap of Thiogenesis Therapeutics? | Thiogenesis Therapeutics' current market cap is $21M. |
| Is Thiogenesis Therapeutics profitable? | No, Thiogenesis Therapeutics is not profitable. |
| What is the current net income of Thiogenesis Therapeutics? | Thiogenesis Therapeutics' last 12 months net income is ($5M). |
| How many companies Thiogenesis Therapeutics has acquired to date? | Thiogenesis Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Thiogenesis Therapeutics has invested to date? | Thiogenesis Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
Lists including Thiogenesis Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.